Edition:
United States

Mesoblast Ltd (MESO.OQ)

MESO.OQ on NASDAQ Stock Exchange Global Select Market

5.41USD
21 Feb 2018
Change (% chg)

$0.11 (+2.08%)
Prev Close
$5.30
Open
$5.35
Day's High
$5.56
Day's Low
$5.35
Volume
12,048
Avg. Vol
10,337
52-wk High
$12.50
52-wk Low
$4.75

Select another date:

BRIEF-Mesoblast Says ‍Primary Endpoint Achieved In A Phase 3 Cell Therapy Trial

* ‍PRIMARY ENDPOINT SUCCESSFULLY ACHIEVED IN MESOBLAST'S PHASE 3 CELL THERAPY TRIAL FOR ACUTE GRAFT VERSUS HOST DISEASE​ Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)

Mesoblast stem cell therapy meets goal of pediatric Graft vs. Host study

Nearly 70 percent of children with potentially fatal acute Graft Versus Host Disease responded to treatment with an experimental stem cell therapy from Mesoblast Ltd, meeting the primary goal of a late-stage U.S. trial, the Australian company announced on Wednesday.

Mesoblast stem cell therapy meets goal of pediatric Graft vs Host study

Feb 21 Nearly 70 percent of children with potentially fatal acute Graft Versus Host Disease responded to treatment with an experimental stem cell therapy from Mesoblast Ltd, meeting the primary goal of a late-stage U.S. trial, the Australian company announced on Wednesday.

FDA to fast track Mesoblast's cell therapy for heart failure

Australian drug developer Mesoblast Ltd said on Thursday the U.S. Food and Drug Administration would fast track the review of its cell therapy treatment for heart failure patients under a new designation rolled out last December.

FDA to fast track Mesoblast's cell therapy for heart failure

Dec 21 Australian drug developer Mesoblast Ltd said on Thursday the U.S. Food and Drug Administration would fast track the review of its cell therapy treatment for heart failure patients under a new designation rolled out last December.

BRIEF-Mesoblast Gets Regenerative Medicine Advanced Therapy Designation From U.S. FDA​

* ‍U.S. FDA GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR ITS MESENCHYMAL PRECURSOR CELL THERAPY ​ Source text for Eikon: Further company coverage:

BRIEF-Mesoblast's Phase 3 Trial In Children With Acute Graft Versus Host Disease Completes Enrollment

* MESOBLAST'S PHASE 3 TRIAL IN CHILDREN WITH ACUTE GRAFT VERSUS HOST DISEASE COMPLETES ENROLLMENT

BRIEF-Mesoblast Says Granted Tigenix Access To Certain Of Its Patents

* ‍HAS GRANTED TIGENIX EXCLUSIVE ACCESS TO CERTAIN OF ITS PATENTS TO SUPPORT GLOBAL COMMERCIALIZATION OF STEM CELL PRODUCT CX601​ Source text for Eikon: Further company coverage:

BRIEF-Tigenix Nv - Mesoblast Grants Access To Patents To Support Commercialization Of Adipose-Derived Mesenchymal Stem Cell Product Cx601 For Treatment Of Fistulae​

* - MESOBLAST GRANTS ACCESS TO PATENTS TO SUPPORT COMMERCIALIZATION OF ADIPOSE-DERIVED MESENCHYMAL STEM CELL PRODUCT CX601 FOR TREATMENT OF FISTULAE​

BRIEF-MESOBLAST PHASE 2 TRIAL RESULTS SHOW DURABLE EFFECTS IN ARTHRITIS PATIENTS

* MESOBLAST PHASE 2 TRIAL RESULTS SHOW EARLY AND DURABLE EFFECTS OF SINGLE MESENCHYMAL PRECURSOR CELL INFUSION IN BIOLOGIC REFRACTORY RHEUMATOID ARTHRITIS PATIENTS

Select another date: